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Background: We compared adjunctive treatment with placebo, dexamethasone, anti-C5 antibodies, and the
combination of dexamethasone plus anti-C5 antibodies in experimental pneumococcal meningitis.
Methods: In this prospective, investigator-blinded, randomized trial, 96 mice were infected intracisternally with
107 CFU/ml Streptococcus pneumoniae serotype 3, treated with intraperitoneal ceftriaxone at 20 h, and randomly
assigned to intraperitoneal adjunctive treatment with placebo (saline), dexamethasone, anti-C5 antibodies, or
dexamethasone plus anti-C5 antibodies. The primary outcome was survival during a 72-h observational period that
was analyzed with the log-rank test. Secondary outcome was clinical severity, scored on a validated scale using a
linear mixed model.
Results: Mortality rates were 16 of 16 mice (100 %) in the placebo group, 12 of 15 mice (80 %) in the dexamethasone
group, 25 of 31 mice (80 %) in the anti-C5 antibody group, and 18 of 30 mice (60 %) in the dexamethasone plus anti-C5
antibody group (Fisher’s exact test for overall difference, P = .012). Mortality of mice treated with dexamethasone
plus anti-C5 antibodies was lower compared to the anti-C5 antibody-treated mice (log-rank P = .039) and
dexamethasone-treated mice (log-rank P = .040). Clinical severity scores for the dexamethasone plus anti-C5
antibody-treated mice increased more slowly (0.199 points/h) as compared to the anti-C5 antibody-treated mice
(0.243 points/h, P = .009) and dexamethasone-treated mice (0.249 points/h, P = .012). Modeling of severity data
suggested an additive effect of dexamethasone and anti-C5 antibodies.
Conclusion: Adjunctive treatment with dexamethasone plus anti-C5 antibodies improves survival in severe
experimental meningitis caused by S. pneumoniae serotype 3, posing an important new treatment strategy for
patients with pneumococcal meningitis.
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Mortality and morbidity rates are high among adults
with acute bacterial meningitis, especially those with
pneumococcal meningitis [1]. Unfavorable neurologic
outcomes are not the result of treatment with inappro-
priate antimicrobial agents, since cerebrospinal fluid
cultures are sterile 24 to 48 h after the start of anti-
biotic therapy [2]. Studies in animals have shown that
bacterial lysis, induced by treatment with antibiotics,
leads to inflammation in the subarachnoid space, which
may contribute to an unfavorable outcome [2]. These
studies also show that adjuvant treatment with anti-
inflammatory agents, such as dexamethasone, reduces
both cerebrospinal fluid inflammation and neurologic
sequelae [2].
This knowledge has prompted many clinical trials on
the effect of dexamethasone in acute bacterial meningi-
tis. A Cochrane meta-analysis showed that adjunctive
dexamethasone treatment did not reduce mortality in
children with bacterial meningitis but did decrease
hearing loss from 20 % in the control group to 15 % in
corticosteroid-treated children (risk ratio (RR) 0.74;
95 % CI 0.62–0.89) [3]. For adults with community-
acquired bacterial meningitis, the results of a European
controlled trial showed that adjunctive dexamethasone,
given before or with the first dose of antibiotic therapy,
was associated with a reduction in mortality (7 vs.
15 %; RR 0.48; 0.24–0.96) [4]. This beneficial effect was
most obvious in adults with pneumococcal meningitis,
in whom the mortality rate decreased from 34 to 14 %.
Novel treatment strategies are needed to further im-
prove prognosis of bacterial meningitis. In a nationwide
genetic association study, we found that complement
activation plays a crucial role in the outcome of patients
with pneumococcal meningitis [5]. We showed that
inhibition of complement component C5 with monoclo-
nal antibodies decreased mortality in a pneumococcal
meningitis mouse model [5]. In this study, mice were
inoculated with serotype 2 pneumococci, an uncommon
serotype in patients [1]. Differences in virulence between
pneumococcal serotypes may affect the efficacy of ad-
junctive treatments [6]. Furthermore, anti-C5 antibody
treatment was not administered together with dexa-
methasone, which is currently the standard therapy in
pneumococcal meningitis [7]. Finally, in recent years,
new standards for animal experiments have been pro-
posed to improve the predictive value of preclinical
(animal) research [8]. These included randomization,
blinding, sample size calculations, and standards for
data handling in animal experiments in a similar fash-
ion to protocols routine in clinical trials.
The aims of the current study were (1) to validate the
beneficial effect of anti-C5 antibodies in a pneumococcal
meningitis mouse model using a common pneumococcalserotype [1, 9] and (2) to assess the potential added
benefit of combining anti-C5 antibody treatment with
adjunctive dexamethasone in a randomized investigator-
blinded trial.
Methods
A well-characterized mouse model of pneumococcal men-
ingitis was used in this study [10]. Nine- to 11-week-old
male C57BL/6NCrl mice (Charles River Laboratories,
Germany) were injected with 1 μl of 107 CFU/ml Strepto-
coccus pneumoniae serotype 3 (ATCC 6303; American
Type Culture Collection, Rockville, MD, USA) into the
cisterna magna under short-term isoflurane anesthesia.
We first evaluated whether the expression profile of
the terminal complement complex (C5b-9) was similar
in mice infected with serotype 3 compared to previous
observations in a serotype 2 model. Mice were inocu-
lated and sacrificed at 6 h (n = 12) and 24 h (n = 12)
after infection. Mice inoculated with sterile saline and
sacrificed at 24 h (n = 6) served as control. After euthan-
asia, mice were perfused with sterile phosphate-buffered
saline, the brain was removed and the left hemisphere was
taken up in 20 % weight per volume sterile saline and
homogenized with a tissue homogenizer. Bacterial titers
were determined by plating serial 10-fold dilutions on
sheep-blood agar plates and incubating for 16 h at 37 °C.
Subsequently, brain homogenates were lysed in lysis buffer
(150 mM NaCl, 15 mM Tris, 1 mM MgCl2, 1 mM CaCl2,
1 % Triton, 4 μl/ml AEBSF, 50 μg/ml EDTA-Na2, 10 ng/
ml pepstatin, 10 ng/ml leupeptin, pH 7.4) on ice for
20 min and centrifuged at 3600 rpm at 4 °C for 15 min.
The supernatant was stored at −20 °C until assayed. C5b-
9 levels were determined in brain homogenates by ELISA
(USCN Life Science).
Subsequently, we performed a randomized investigator-
blinded trial. All mice were treated intraperitoneally 20 h
after infection with a single dose of ceftriaxone
(100 mg/kg) in combination with adjuvant treatment. Ad-
juvant treatment was administered once together with the
antibiotics and consisted of sterile saline (n = 16; “placebo
group”), dexamethasone (0.5 mg/kg, n = 16), a neutralizing
antibody against C5 (clone BB5.1; 1 mg/mouse, n = 32), or
dexamethasone plus anti-C5 antibodies in previously men-
tioned doses (n = 32); groups were randomized in a ratio
1:1:2:2. To compare anti-C5 antibody-treated mice with
non-anti-C5 antibody-treated mice and dexamethasone-
treated mice with non-dexamethasone-treated mice, we
aimed to detect a decrease in mortality from 80 to 50 %.
Using an 80 % power, one-sided testing, and significance
level of P < .05, we needed 32 mice per combined group.
Since we were most interested in the comparison be-
tween the anti-C5 antibody-treated group and the dexa-
methasone plus anti-C5 antibody-treated group, we
randomized in a 1:1:2:2 ratio, in which twice as many
Fig. 1 C5b-9 is expressed in brain during experimental pneumococcal
meningitis. C5b-9 (μg/mg) protein levels in brain of WT mice inoculated
with sterile saline (n= 6) or 107 CFU/ml of S. pneumoniae serotype 3
(n = 24) and sacrificed at 6 or 24 h post inoculation. Mice with
pneumococcal meningitis showed increased brain C5b-9 levels
compared to saline-inoculated mice at 24 h after inoculation (median
0.78 vs. 2.53 μg/mg tissue, Mann-Whitney U test P = .001). Lines
represent median values
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and dexamethasone plus anti-C5 antibody group com-
pared to the placebo- and dexamethasone-treated groups.
All mice received identical total amount of fluids. Mice
were randomly assigned to treatment groups using a
computer-generated random number list (Microsoft
Excel 2010), and all researchers were blinded for treat-
ment allocation. The randomization code was broken
after the last experiment was finished. All animals were
clinically examined and scored prior to inoculation, dir-
ectly following inoculation and at regular intervals dur-
ing the 72-h observation period. The following clinical
features were scored: weight loss, activity, time to return
to upright position, state of fur, posture, eye discharge or
protrusion, respiration rate, irregular/labored breathing,
epilepsy, limb paresis, and coordination [9]. A score of 0
indicates healthy mice, and mice with a score of 15 or
more were terminally ill and therefore euthanized. Hu-
mane endpoints other than the score of 15 or more at
which the mice were euthanized were >25 % weight
loss, ≥2 seizures per 15 min, status epilepticus, and hemi-
paralysis. Mice were euthanized by intraperitoneal injection
of ketamine (190 mg/kg, Eurovet Animal Health, Bladel,
the Netherlands) in combination with dexmedetomidine
(0.3 mg/kg, Pfizer Animal Health, Capelle aan den Ijssel,
the Netherlands). The experiments were performed in
three tranches; all treatment groups were represented in
these tranches. The number of colony-forming units
(CFUs) in inoculates was determined for each experi-
ment by serial dilutions on sheep-blood agar plates.
Animal experiments were approved by the Institu-
tional Animal Care and Use Committee of the Aca-
demic Medical Center Amsterdam.
The Mann-Whitney U test was used to compare C5b-
9 levels between groups. In the randomized investigator-
blinded trial, survival was analyzed using a log-rank test.
To model the clinical scores of these mice, several
(non)linear mixed models were compared using the
likelihood ratio test statistic (LRTS) or Akaike’s A infor-
mation criterion (AIC). A linear mixed model with a
random slope and fixed effects for dexamethasone (D)
and/or anti-C5 antibody treatment, time, and the interac-
tions between dexamethasone and time and anti-C5 anti-
body treatment and time modeled the data the best (fixed
effects: D + anti-C5 antibodies + Time +D*Time + anti-C5
antibodies*Time). Differences were considered significant
at a P value of <.05.
Results
Bacterial meningitis was confirmed in all mice infected
with S. pneumoniae serotype 3 by determination of CFU
in brain homogenates, showing similar bacterial titers
per time-point (data not shown). C5b-9 levels were de-
termined in brain homogenates of these 30 mice. Micewith pneumococcal meningitis showed increased brain
C5b-9 levels compared to saline-inoculated mice at
24 h after inoculation (median 0.78 vs. 2.53 μg/mg tis-
sue, P = .001; Fig. 1).
In the randomized investigator-blinded trial, 96 C57BL/
6NCrl male mice were injected into the cisterna magna
with S. pneumoniae serotype 3. The number of CFUs in
inoculates was similar between tranches (1.21 × 107,
0.94 × 107, 1.22 × 107 CFU/ml). Four mice showed a limb
paresis directly following inoculation and were subse-
quently taken out of the experiment and euthanized. All
remaining mice showed signs of illness 20 h after infec-
tion and were randomly assigned to the four treatment
groups: 16 mice to the placebo group, 15 mice to the
dexamethasone group, 31 mice to the anti-C5 antibody
group, and 30 mice to the dexamethasone plus anti-C5
antibody group. All mice were treated intraperitoneally
with ceftriaxone.
The first animals reached an endpoint at 26 h after
infection, and the overall mortality rate during the 72-h
observation period was 71 of 92 (77 %). The mortality
rates were 16 of 16 mice (100 %) in the placebo group,
12 of 15 mice (80 %) in the dexamethasone group, 25 of
31 mice (80 %) in the anti-C5 antibody group, and 18 of
30 mice (60 %) in the dexamethasone plus anti-C5 anti-
body group (Fig. 2a; Fisher’s exact test for overall differ-
ence, P = .012). The combination of dexamethasone and
anti-C5 antibodies resulted in a significant reduction in
mortality compared to placebo (log-rank P < .001), anti-
C5 antibodies (log-rank P = .039), and dexamethasone
(log-rank P = .040). Adjuvant dexamethasone signifi-
cantly reduced mortality when all treatments with
dexamethasone were compared to all treatments
Fig. 2 (See legend on next page.)
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Fig. 2 Adjuvant treatment with dexamethasone plus anti-C5 antibodies reduces mortality in experimental pneumococcal meningitis.
Kaplan-Meier survival curves of WT mice inoculated with 107 CFU/ml of S. pneumoniae serotype 3 and treated at 20 h after infection with
ceftriaxone (100 mg/kg) in combination with adjuvant treatment. Adjuvant treatment consisted of sterile saline (n = 16; “placebo group”),
dexamethasone (0.5 mg/kg, n = 15), a neutralizing antibody against C5 (C5-Ab; 1 mg/mouse; clone BB5.1, n = 31), or dexamethasone plus
anti-C5 antibodies in previously mentioned doses (n = 30). a Adjuvant treatment with dexamethasone plus anti-C5 antibodies resulted in a
significant reduction in mortality compared to placebo (log-rank P < .001), anti-C5 antibodies, (log-rank P = .039), and dexamethasone
(log-rank P = .040). b Adjuvant dexamethasone significantly reduced mortality when all treatments with dexamethasone were compared to
all treatments without dexamethasone (log-rank P = .024). c Treatments with anti-C5 antibodies significantly reduced mortality when
compared to all treatments without anti-C5 antibodies (log-rank P = .006)
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log-rank P = .024; Fig. 2b). Treatments with anti-C5 anti-
bodies significantly reduced mortality when compared to
all treatments without anti-C5 antibodies (mortality rate 71
vs. 90 %, log-rank P = .006; Fig. 2c). Clinical severity scores
for the dexamethasone plus anti-C5 antibody-treated mice
increased slowly as compared to dexamethasone-treated
mice (0.199 vs. 0.249 points/h, P = .012), anti-C5 antibody-
treated mice (0.199 vs. 0.243 points/h, P = .009), and
placebo-treated mice (0.199 vs. 0.293 points/h, P = .001).
When analyzing dexamethasone vs. no dexamethasone
treatment, a slower increase of the clinical score with time
was observed (reduction 0.044 ± 0.018 points/h, P = .013).
This effect was independent of anti-C5 antibody treatment
that also caused a slower increase of the clinical score
with time (reduction 0.050 ± 0.019 points/h, P = .009)
compared to no anti-C5 antibody treatment. A model
with inclusion of a D*C5*Time interaction did not sig-
nificantly improve fitting of the data (P = .317). This
indicates that the effects of dexamethasone and anti-
C5 antibody treatments on clinical score are additive
with no synergistic enhancement.
Discussion
The results of our randomized study show that adjunctive
treatment with dexamethasone plus anti-C5 antibodies is
beneficial in experimental pneumococcal meningitis.
Adjunctive treatment with dexamethasone plus anti-C5
antibodies led to lower clinical severity scores and im-
proved survival. The observed effects of this combined
adjunctive therapy were superior to that observed in ani-
mals adjunctively treated with dexamethasone or anti-C5
antibodies alone. Since anti-C5 antibodies are currently
licensed for clinical use (Eculizumab™) and other anti-C5
agents are in clinical trials [11–14], our results present a
promising treatment option for future patients with
community-acquired pneumococcal meningitis, although
the current treatment costs are an important limiting
factor for future studies and implementation.
We previously demonstrated that a common variant
in complement component 5 was associated with un-
favorable outcome in adults with community-acquired
pneumococcal meningitis [5]. The anaphylatoxin C5a
was identified as the crucial complement product inpneumococcal meningitis. Deficiency of the receptor
for C5a led to an improved clinical status and clinical
course in mice. C5a receptor deficiency and C5
neutralization resulted in a marked reduction of CSF
WBC counts in the pneumococcal mouse model, with
lower concentrations of IL-6, CXCL1, and CXCL2. Pre-
treatment with CXCL1 and CXCL2 antibodies caused a
reduction of CSF WBC count, but to a lesser extent
than that found in C5ar1−/− mice, indicating that C5a
regulates chemokine expression but also has a direct
chemotactic effect. Neutralization experiments showed
that adjunctive treatment with anti-C5 antibodies im-
proved outcome in mice with pneumococcal meningi-
tis. However, these experiments were performed as a
proof-of-concept, not according to the new standards
for animal experiment [8]. In these experiments, infec-
tion was induced using S. pneumoniae serotype 2, a
very uncommon cause of bacterial meningitis [1]. We
have now showed the therapeutic effect of neutralizing
antibodies against C5 in a randomized controlled man-
ner, using S. pneumoniae serotype 3, a common
pneumococcal serotype [1, 9].
Our results show a beneficial effect of adjunctive dexa-
methasone on clinical severity and survival. Dexametha-
sone has become routine in patients with pneumococcal
meningitis as result of clinical trials and meta-analyses
[3, 4, 15–18]. The mechanisms by which dexamethasone
inhibits inflammation are not clear, but it decreases pro-
inflammatory cytokine production in monocytes, den-
dritic cells, astroglial cells, and neutrophils, increases
the production of anti-inflammatory cytokines such as
IL-10, inhibits ROS production by leukocytes, and de-
creases leukocyte adherence [2]. Dexamethasone also
acts on multiple molecules of the TLR downstream sig-
naling cascade [2]. A nationwide implementation of
dexamethasone therapy reduced the nationwide mortal-
ity rate of adult pneumococcal meningitis from 30 to
20 % in the Netherlands [9].
In the current study, we investigated the additive
effect of these two adjunctive anti-inflammatory ther-
apies, dexamethasone and anti-C5 antibodies. We
used a randomized investigator-blinded trial with large
group sizes to investigate this new therapeutic strategy
in experimental pneumococcal meningitis. To our
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junctive therapy on clinical course and survival in ex-
perimental pneumococcal meningitis. Nevertheless,
our study has several limitations, mainly limiting our
external validity towards the human situation. First,
antibiotic treatment was only given once at 20 h, dur-
ing an observation period of 72 h, while in clinical
practice, patients are treated twice a day with ceftriax-
one; further, mice were treated with a single dose of
dexamethasone, while dexamethasone is given four
times daily for 4 days in patients [3, 7, 18, 19]. These
dosing regimens, chosen to keep the treatment regi-
men comparable to the previous published experiment
[5], can be regarded as common practice in animal
studies but may have led to a underestimation of the
effect of dexamethasone. We observed a higher mor-
tality than expected in the experiments (50 % expected
vs. 60 % observed in the treatment group, 80 % ex-
pected vs. 100 % observed in the placebo group) which
may have contributed to the significance of the results.
The severity of pneumococcal meningitis varies be-
tween experiments, which can be caused by variation
in bacterial virulence.
Differences between pneumococcal serotypes may
affect the efficacy of anti-C5 antibody treatment. We
showed that inhibition of complement component C5
improves outcome in serotypes 2 and 3 pneumococcal
meningitis [5], suggesting the effect of anti-C5 anti-
bodies is serotype independent. However, for serotypes
other than 2 and 3, data are currently lacking on anti-C5
antibody treatment. We chose serotype 3 for our mouse
model as it was the most common serotype in a clinical
cohort performed in the Netherlands [1, 10]. Although
following introduction of conjugate vaccines, the propor-
tion of cases due to serotype 3 has decreased, it is still
among the most common serotypes in adult pneumo-
coccal meningitis [9, 20].
The effect of anti-C5 antibody treatment in bacterial
meningitis caused by pathogens other than S. pneumo-
niae is unclear and should be studied separately.
Whereas dexamethasone was shown to be of no harm in
meningococcal meningitis, complement inhibition may
be detrimental, as the role of complement was found to
be substantially different between pneumococcal and
meningococcal meningitis [21, 22].
In conclusion, in a randomized investigator-blinded
study, we observed a strong protective effect of adjunct-
ive treatment with dexamethasone plus anti-C5 anti-
bodies. Our data provide further evidence for the
efficacy of complement inhibition in pneumococcal
meningitis, supporting the need for a phase II clinical
trial to evaluate the effect of combined adjunctive dexa-
methasone plus C5-antibody treatment in patients with
pneumococcal meningitis.Competing interests
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